Suggested remit: To appraise the clinical and cost effectiveness of apalutamide within its marketing authorisation for treating localised hormone-relapsed prostate cancer.
Following on from information provided to NICE by the company in June 2019, the appraisal of Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1174
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Janssen (apalutamide)
- Others
- Department of Health and Social Care
- NHS England
- NHS North East Hampshire and Farnham CCG
- NHS Swale CCG
- Welsh Government
- Patient carer groups
- Black Health Agency
- Bob Champion Cancer Trust
- Cancer Black Care
- Cancer Equality
- HAWC
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Muslim Council of Britain
- Orchid
- Pelican Cancer Foundation
- PCaSO - Prostate Cancer
- Prostate Cancer UK
- Prostate Help Association
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tackle Prostate Cancer
- Tenovus Cancer Care
- Professional groups
- Association of Anaesthetists
- Association of Cancer Physicians
- Association of Surgeons of Great Britain and Ireland
- British Association of Urological Nurses
- British Association of Urological Surgeons
- British Geriatrics Society
- British Institute of Radiology
- British Prostate Group
- British Psychosocial Oncology Society
- British Uro-Oncology Group
- Cancer Research UK
- Prostate Cancer Advisory group
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Health Forum
- UK Oncology Nursing Society
- Urology Foundation
- Associated public health groups
- Public Health England
- Public Health Wales
- Comparator companies
- Accord (bicalutamide)
- Astellas Pharma (enzalutamide)
- AstraZeneca UK (bicalutamide, goserelin)
- Bayer (cyproterone acetate)
- Concordia International (leuprorelin)
- Ferring Pharmaceuticals (degarelix, triptorelin)
- Generics UK T/A Mylan (flutamide)
- Ipsen (triptorelin)
- Orion Pharma UK (histrelin)
- Sanofi (buserelin)
- Sunpharma (bicalutamide)
- Takeda UK (leuprorelin)
- Wockhardt UK (cyproterone acetate)
- Zentiva (bicalutamide)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- Cochrane Urology
- Everyman
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Ovarian & Prostate Cancer Research Trust
- Pro Cancer Research Fund
- Prostate Cancer Research Centre
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in June 2019, the appraisal of Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 07 May 2020 | Note added to the project documents |
| 25 June 2019 | Note added to the project documents |
| 15 February 2019 | Note added to the project documents |
| 15 February 2019 | Suspended. Suspended |
| 29 November 2018 | Invitation to participate |
| 08 August 2018 - 06 September 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 13 February 2018 | In progress. DHSC referral date received |
For further information on our processes and methods, please see our CHTE processes and methods manual